EATL : Prognosis
Prognosis: Enteropathy-associated T-cell lymphoma (EATL) is a multifocal disease with a high rate of intestinal recurrence. The prognosis is poor with a median survival of 7 months and 1-yr survival rate of 30%-40%. The shortened long-term survival is due to malnutrition, which is common in patients with EATL and prior type II refractory celiac disease. Since this disease is most commonly seen in older patients, many are poor candidates for chemotherapy. Improved survival has been reported in patients who are able to tolerate intensive chemotherapy followed by autologous stem cell transplantation. This image from a case of EATL shows edge of a necrotic area with karyorrhectic debris and scattered tumor cells.